Recovery
KLOW
A seller’s name for one blend vial. Most listings put four peptides in it: GHK-Cu, KPV, BPC-157 and TB-500, usually 80 mg in all. The split between them changes by seller, so your vial’s COA is the list that counts.
At a glance
- What is in it
- Sold as
- One blended vial
- The evidence
- There is no published study of any four-compound formulation of this kind. Three of the four components are pro-angiogenic, which compounds the cancer caution rather than adding benefit. KPV, the component that supposedly gives the name its K, has zero human data of any kind. FDA searched and found no clinical studies, no pharmacokinetics and no pharmacodynamics by any route.Combination-specific research is limited. Treat each compound’s evidence as separate unless a study of the combination itself is named here, and review the complete plan with a qualified clinician.
Running this stack, with the schedule, the vials it takes and a log of what you took, happens in the app: Claritide for iPhone.
Why people explore it
Common reasons for exploring it
- Lifters, runners and recreational athletes working on a soft tissue injury who want the local and the systemic repair compound in the same draw
- People whose recovery comes with an inflammatory or gut component, which is what the KPV in it is used for
- People who also want the collagen and elastin side of the GHK-Cu argument
- People who would otherwise buy four vials and want one draw instead of four
- Anyone who already owns a vial with these four letters on it and wants to know what a draw actually delivers
- Anyone who wants a worked example of why a blend name is not a formulation
Where clinician input matters
- Anyone who has not run these compounds individually first. Four compounds in one syringe removes any ability to attribute a result or a side effect.
- Anyone with active or recent cancer, or a significant family cancer history
- Anyone with Wilson's disease
- Drug-tested athletes
- Pregnant or nursing, under 25
The science
Read the compound mechanisms
GHK-Cu does two jobs at once: it signals, and it carries copper. As a signal, genomic work using the Broad Institute's Connectivity Map found it modulates expression of over 4,000 human genes, activating repair genes and suppressing genes tied to inflammation and tissue breakdown. That is an epigenetic effect rather than a surface one: it shifts the gene expression profile of aged cells toward patterns seen in younger tissue. As a carrier, it delivers copper to the enzyme lysyl oxidase, which cross-links collagen and elastin fibres into their functional, load-bearing form. Without copper, newly made collagen is structurally weak. It also directly stimulates fibroblasts to produce collagen types I and III, elastin and glycosaminoglycans, and coordinates the breakdown of damaged tissue with the deposition of properly organised replacement tissue rather than scar.
The story you will read everywhere is that KPV is a melanocortin receptor agonist, and FDA says that is probably wrong. In its 2026 briefing document FDA writes that several lines of evidence suggest melanocortin receptors are unlikely to be the molecular targets behind KPV, because KPV could not displace radiolabelled alpha-MSH binding in rat brain tissue, in murine melanoma cells or in MC1R-expressing macrophages, and did not raise cAMP in those macrophages. What FDA does consider plausible is inhibition of NF-κB, the master switch that turns on pro-inflammatory cytokine genes, plus inhibition of interleukin-1β effects. The third piece is transport: KPV is taken up into human intestinal epithelial cells and Jurkat T cells through PepT1, a peptide transporter that is upregulated in inflamed gut tissue. That last detail is the one that makes the gut argument mechanically coherent: the transporter that carries it in is more abundant exactly where the inflammation is.
BPC-157 appears to work by improving the blood supply to damaged tissue and then telling the repair machinery to switch on. It increases expression of VEGFR2, a receptor that drives angiogenesis, the growth of new blood vessels, so more oxygen and nutrients reach the injury. It also interacts with the nitric oxide system, which controls how wide blood vessels open and how strongly the inflammatory response fires, counteracting both too little and too much nitric oxide. Separately it raises growth hormone receptor expression in tendon fibroblasts and activates the FAK-paxillin pathway, the signalling route cells use to stick, crawl and divide during wound repair. It is named for a cytoprotective effect: shielding tissue from NSAIDs, alcohol and other stressors. That effect is most pronounced in the gut.
Read the molecule before the mechanism. TB-500 is the acetylated seven-amino-acid fragment Ac-LKKTETQ, residues 17–23 of the 43-amino-acid parent, Thymosin Beta-4. Everything that follows is Thymosin Beta-4's pharmacology, and FDA states that acetylation irreversibly alters charge, hydrophobicity and size, so results for the parent cannot be extrapolated to TB-500. The mechanism below is inherited by argument, not demonstrated for this compound. Thymosin Beta-4 is the main G-actin sequestering peptide in cells. Actin is the scaffolding protein that gives a cell its shape and lets it crawl; by binding free actin monomers, it regulates that scaffolding and therefore controls cell shape, motility and division. The practical result, in lab and animal studies, is that repair cells migrate toward wound sites. It upregulates migration across several cell types at once: keratinocytes, endothelial cells, stem cells. It also reduces inflammatory markers and has shown anti-fibrotic properties, meaning less scar tissue laid down during healing. TB-500 carries the stretch of the parent that binds actin. FDA says it remains to be determined whether that binding explains any healing effect, and in the one cell-culture test of TB-500 itself, it did not close scratch wounds in cultured cells.
No standard dose publishedRead the COA, not the name. This is a name printed on a vial rather than a protocol, and the composition changes by vendor. We publish no dose for it and the builder will not prefill one. Enter your own vial’s composition and derive each figure from it.
Components
| Compound | What it is here for | Reported mg |
|---|---|---|
| GHK-Cu | The skin component: copper carried to the enzyme that cross-links collagen and elastin |
|
| KPV | The anti-inflammatory component, studied in gut and skin inflammation |
|
| BPC-157 | Local tissue repair, with an angiogenic effect our sources describe as local to the injection |
|
| TB-500 | Described as body-wide tissue repair, rather than acting where it lands |
|
- GHK-Cu: The skin and copper component. GHK-Cu carries copper to lysyl oxidase, the enzyme that cross-links collagen and elastin into their load-bearing form, and it stimulates fibroblasts to produce collagen types I and III, elastin and glycosaminoglycans. The trials behind that are topical; the injected route has none. PSPeptides sells 30 mg of an 80 mg vial. Copper reference points: adult RDA 900 mcg/day, tolerable upper intake 10,000 mcg/day.
- KPV: The anti-inflammatory component, and the one that supposedly gives the name its K. KPV is the last three amino acids of alpha-MSH. FDA considers the melanocortin-receptor story that circulates about it unlikely, and puts the plausible mechanism at inhibition of NF-κB, the master switch that turns on pro-inflammatory cytokine genes, plus inhibition of interleukin-1β effects. It is carried into gut cells by PepT1, a transporter that is more abundant exactly where the inflammation is. The rodent colitis and wound-healing data behind all of that is real and reasonably consistent. PSPeptides sells 10 mg of an 80 mg vial. KPV has no human data of any kind, so there is no dose to compare yours against.
- BPC-157: The local repair component. BPC-157 raises expression of VEGFR2, the receptor that drives the growth of new blood vessels, so more oxygen and nutrients reach damaged tissue; it works on the nitric oxide system that governs how wide vessels open and how hard inflammation fires, and it activates the FAK-paxillin pathway cells use to stick, crawl and divide during wound repair. That angiogenic effect is described as local, which is why injection proximity matters for it. PSPeptides sells 20 mg of an 80 mg vial.
- TB-500: Described as the body-wide repair component, the counterpart to BPC-157 rather than a second copy of it, so injection site relative to an injury is treated as mattering much less. What it is described as doing is moving repair cells toward wound sites across keratinocytes, endothelial cells and stem cells at once, lowering inflammatory markers, and laying down less scar tissue. FDA is explicit that this mechanism is inherited from the 43-amino-acid parent by argument and has never been demonstrated for the fragment itself. PSPeptides sells 20 mg of an 80 mg vial.
- Duration
- No cycle length is published by any source we can stand behind. The titration ladder and the reconstitution arithmetic circulating for this blend come from a single affiliate page and are not reproduced here.
Reported compositions
None of these is “the” composition. Switching vendors at the same product name and the same total milligrams can change a single component by 2×, with nothing on either label to tell you. That is why the only figure worth trusting here is the one on your own vial’s certificate of analysis.
Dominant reading: GLOW plus KPV, the four compounds 7 of 8 vendor and affiliate pages list. Not seven independent sources: one content genre repeating itself, and one of the "sources" is a vendor's own paid press release. This seller calls 50/10/10/10 the standard 80 mg split.
Mixing each compound
Not established in available literature. Use the figures printed on your own vial.
Not established in available literature. Use the figures printed on your own vial.
- 10 units = 0.25 mg
- 20 units = 0.5 mg
- 30 units = 0.75 mg
- 40 units = 1 mg
- 60 units = 1.5 mg
- 100 units = 2.5 mg
- 80 units = 2 mg
- 60 units = 1.5 mg
- 40 units = 1 mg
- 20 units = 0.5 mg
Week by week
GHK-Cu
- Week 1–4 (topical)
Skin texture begins to smooth. Not visible yet: collagen gene activation takes time. Post-procedure healing after microneedling or laser is noticeably faster.
- Week 4–8 (topical)
First visible changes. Skin appears more hydrated and firmer, fine lines begin softening, tone becomes more even.
- Week 8–12 (topical)
Full results as measured in clinical trials: reduced wrinkle depth, increased skin density and thickness, improved elasticity.
- Month 3+ (topical)
Cumulative improvement. The longer it runs, the more collagen accumulates.
- Week 1–2 (injectable)
Wound healing effects appear earliest; reduced inflammation at injury sites.
- Week 4–8 (injectable)
Systemic effects reported: hair growth, joint recovery, skin quality. Note this route has no human trial support.
BPC-157
- Week 1–2
Subtle. Reduced inflammation, warmth or increased blood flow near the injection site, slight pain reduction. Some people feel nothing yet. The Playbook describes this as normal.
- Week 3–4
Noticeable improvement in most reports. Pain drops on movements that previously hurt, range of motion improves, swelling decreases.
- Week 5–6
People describe significant functional recovery for acute injuries in this window. Chronic injuries may need a second cycle.
- Week 6–8+
For stubborn or chronic problems, a second cycle after a 2–4 week break often brings further improvement. Chronic tendinopathy may need two full cycles.
- After stopping
Benefits generally persist. The Playbook frames this as tissue actually repairing rather than pain being masked.
TB-500
- Week 1–2
Subtle. Reduced inflammation and mild pain reduction are the commonly described early signals.
- Week 2–3
Our recovery guide places initial noticeable change here, later than BPC-157, and reads that as a body-wide rather than local effect.
- Week 4–6
Loading phase completes. Functional improvement in soft tissue injuries; the dosing schedule drops to weekly.
- Week 6–8
Our recovery guide describes significant improvement in this window for TB-500 run solo.
What it costs
- GHK-Cu: $30–80 per month (1–2% serum, 30 mL)
- KPV: Not established in available literature
- BPC-157: $80–120 per 4–6 week cycle (two 5 mg vials)
- TB-500: $80–120 per 4–6 week cycle (two 5 mg vials)
These figures are published over different cycle lengths, so Claritide does not add them into one number. Log a vial and the cost engine will tell you what this stack costs you per week, from what you actually paid.
Cautions
- Read the COA, not the name. The same four letters can buy you 50 mg of GHK-Cu or 30 mg.
- The vendor-to-vendor dose gap is the safety issue. One vendor sells GLOW as GHK-Cu 50 / BPC-157 10 / TB-500 10 at 70 mg total. Another sells GLOW as GHK-Cu 30 / BPC-157 20 / TB-500 20 at the same 70 mg total, and KLOW as 30 / 20 / 20 / KPV 10 at 80 mg. Switch vendors mid-cycle at the same product name and your BPC-157 dose changes by 2× and your GHK-Cu by 40%, with nothing on either label to tell you.
- The supplier who states it most plainly is a supplier. Protide Health says of KLOW: "The name is an acronym drawn from its components, and it is a supplier SKU identifier rather than a designation with any regulatory or clinical meaning."
- Nobody expands L, O or W. The letters are not an ingredient list and should not be read as one.
- Three of the four components in the dominant reading are pro-angiogenic. Active or recent cancer, or a family cancer history, is the exclusion that matters most here.
- No stability study exists for four peptides sharing one solution. There is no sourced degradation rule, no sourced colour change, and no sourced discard criterion for this blend. Anyone publishing one is publishing something nobody measured.
- Wilson's disease rules this out entirely. It contains copper.
- BPC-157 and TB-500 are both on the WADA prohibited list. KPV is not named on it. We found no approval for KPV, so athletes should treat it as likely prohibited under S0. GHK-Cu is not named on the List, and we do not state a status for it.
- Copper reference points: adult RDA 900 mcg/day, tolerable upper intake 10,000 mcg/day. Gray-market injectables may contain more copper than declared, less than declared, or copper that is not peptide-bound. And the COA is the only way to find out.
Absence from this list does NOT mean safety. It means lack of research.
Keep reading
Every stack here is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.